5:23 PM
 | 
May 02, 2013
 |  BC Extra  |  Company News

FDA panel votes down Delcath's Melblez Kit

FDA's Oncologic Drugs Advisory Committee voted 16-0 that the benefit-risk profile of Melblez Kit chemosaturation system from Delcath Systems Inc. (NASDAQ:DCTH) does not support...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >